Home Newsfeeds Jasper Therapeutics Q2 EPS $(0.29)

Jasper Therapeutics Q2 EPS $(0.29)

Jasper Therapeutics (NASDAQ:JSPR) reported quarterly losses of $(0.29) per share.

byMichael Horton

August 12, 2022

1 minute read

Jasper Therapeutics (NASDAQ:JSPR) reported quarterly losses of $(0.29) per share.

Why Akerna Shares Are Trading Higher By 97%; Here Are 20 Stocks Moving Premarket

By Lisa Levin

January 12, 8:54 AM

Gainers Akerna Corp. (NASDAQ: KERN) rose 97.4% to $1.91 in pre-market trading after the company reported the sale of 365 Cannabis for $2.8 million.

ACER

BrightView Acquires Commercial Landscaping Company Syringa For Undisclosed Sum

By Akanksha Bakshi

August 18, 11:30 AM

BrightView Holdings, Inc. (NYSE:BV) has acquired Syringa Landscape, LLC, a commercial landscaping company based in Boise, Idaho. Deal terms were…

Wells Fargo Maintains Underweight on Ball, Lowers Price Target to $46

By Benzinga Newsdesk

September 23, 8:37 AM

Wells Fargo analyst Gabe Hajde maintains Ball (NYSE:BALL) with a Underweight and lowers the price target from $53 to $46.

BALL

EXCLUSIVE: Ocean Biomedical Closes Initial $10M Tranche of $27M Private Placement

By Vandana Singh

May 16, 7:30 AM

Ocean Biomedical Inc (NASDAQ: OCEA) has closed the initial US $10 million tranche of a total anticipated $27 million principal amount of Senior Secured Convertible Notes in a private placement with Ayrton Capital. The notes will be issued in three tranches:

OCEA

Jasper Therapeutics Q2 EPS $(0.29)

Related Posts

Why Akerna Shares Are Trading Higher By 97%; Here Are 20 Stocks Moving Premarket

BrightView Acquires Commercial Landscaping Company Syringa For Undisclosed Sum

Wells Fargo Maintains Underweight on Ball, Lowers Price Target to $46

EXCLUSIVE: Ocean Biomedical Closes Initial $10M Tranche of $27M Private Placement